AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00815516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: Administered by intravenous infusion
Study NCT00815516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphotericin B deoxycholate
Description: Administered by intravenous infusion
Study NCT02752555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antioxidant (l-cratinine) + modifiable lifestyle factors
Description: All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
Study NCT00865462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrika Bupropion 150 mg XL Tablet, single dose
Description: A: Experimental Subjects received Abrika formulated products under fed conditions
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study NCT04202094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin IV [trastuzumab]
Description: Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
Study NCT00950300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin SC [trastuzumab]
Description: Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
Study NCT00865462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin XL® 150 mg Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
Study NCT01376596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy based intervention immediately
Description: This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
Study NCT01376596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait list
Description: The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
Study NCT03968328 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Take part in interview
Study NCT03968328 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Respond to survey
Study NCT01959828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-3001
Study NCT00516295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00516295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00516295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00516295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV
Study NCT00516295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00516295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00516295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT03146143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrafiltration
Description: ultrafiltration after cardiopulmonary bypass
Study NCT02013050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX942
Study NCT02013050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01252758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol sufate DPI (TBS-7) dose 1
Study NCT01252758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol sufate DPI (TBS-7) dose 2
Study NCT01252758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol sufate DPI (TBS-7) dose 3
Study NCT01252758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01252758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Study NCT03917758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Start of the treatment with SGLT2i.
Study NCT03044873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
Study NCT04202094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scrotum ultrasound
Description: A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
Study NCT04202094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
Study NCT04202094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semen analysis
Description: A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
Study NCT04589988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Removing Environmental Barriers to Independent Living (REBIL)
Description: REBIL is a complex intervention with two essential components: (1) removing environmental barriers and home hazards in the home tailored to the participant's unique abilities and limitations and (2) strategy training with the participant to help participant to be able to identify barriers in the home and community and identify potential resources and strategies to remove the barriers. Treatment includes one assessment session and four 75-minute visits in the home with an occupational therapist over 8 weeks, followed by a 6 -month assessment session by a blinded rater.
Study NCT04589988 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Attentional Control
Description: The waitlist attentional control group will receive an initial assessment session then four 75 minute interview visits from an occupational therapy graduate assistant, followed by a 6-month assessment session by a blinded rater. After the 6-month follow-up is completed this group will receive the REBIL intervention.
Study NCT02511769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WEB-MAP Educational Control Group
Description: OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
Study NCT03952312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oncotool Intervention (symptom reporting + TKI education)
Description: OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study NCT03952312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oncotool Control (health information)
Description: OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study NCT03151525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: AZA treatment after IFX withdrawal for maintenance of remission
Study NCT03151525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: IFX treatment for maintenance of remission
Study NCT03660904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: home made vitrification & thawing kit
Description: home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
Study NCT03660904 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: commercially made vitrification & thawing kit
Description: commercially available vitrification \& thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
Study NCT04660903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat cell transplantation
Description: Up to 75 ml of fatty tissue mixture fluid
Study NCT02511769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB-MAP CBT
Description: Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
Study NCT04573075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ghost ileostomy
Description: a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
Study NCT03044873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
Study NCT01752517 — intervention group
Intervention type: DRUG
Intervention: NI group
Description: vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
Study NCT04573075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: loop ileostomy
Description: a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
Study NCT01746667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Study NCT01746667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Study NCT01219244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction
Description: 6 months of caloric restriction (15 %)
Study NCT04573075 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: no outlet
Description: no further intervention is used after colorectal resection and forming of a primary anastomosis
Study NCT03748212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D935 Cap. 1T
Description: single oral administration under fed condition
Study NCT01219244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: omega-3 supplementation
Description: 6 months of omega-3 supplementation
Study NCT01219244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resveratrol supplementation
Description: 6 months of resveratrol supplementation
Study NCT03173534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN
Description: WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
Study NCT03173534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement
Study NCT03173534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement
Study NCT04163679 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal Preparation
Description: One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick.
Study NCT04163679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Preparation
Description: One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick.
Study NCT05696860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography Monitoring
Description: Capnography monitoring
Study NCT03237871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-message survey and informational text messages
Description: Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
Study NCT00911742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD
Description: 1 Tramadol Contramid OAD 200 mg tablet as a single dose
Study NCT00911742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zytram
Description: 1 Zytram 200 mg tablet as a single dose
Study NCT03748212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-385 Tab. 1T
Description: single oral administration under fed condition
Study NCT02902601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446, 600 mg
Description: Participants will receive JNJ-54175446, 600 mg as an oral suspension.
Study NCT02902601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446, 150 mg
Description: Participants will receive JNJ-54175446, 150 mg as an oral suspension.
Study NCT02902601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-54175446
Study NCT02902601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to JNJ-54175446
Study NCT03531060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL790
Description: IRL790 capsule 10 mg
Study NCT03531060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT04835116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.
Description: Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.
Study NCT04835116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.
Description: Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
Study NCT01219244 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months of placebo intake
Study NCT01219244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2nd step: intervention + physical / cognitive training
Description: most effective dietary intervention plus physical and cognitive training
Study NCT01219244 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 2nd step: intervention + control
Description: most effective dietary intervention plus control